Abstract
Talaromycosis is a life-threatening fungal disease commonly seen in patients with acquired immunodeficiency syndrome (AIDS), which is endemic in Southern China and Southeast countries. The diagnostic methods available for talaromycosis are relatively time-consuming and yield a high mortality. Therefore, early diagnosis of talaromycosis is extremely important. We aimed to determine a potential method for assisting in its early diagnosis. A total of 283 patients with AIDS admitted to our hospital were prospectively included in this cross-sectional study and divided into those with Talaromyces marneffei (TSM group, n = 93) and those without Talaromyces marneffei (non-TSM group, n = 190). The diagnostic accuracy of the Mp1p enzyme immunoassay (EIA), galactomannan (GM) assay, and blood culture performed within 3 days of hospitalisation were evaluated, using talaromycosis confirmed by culture and/or pathology as the gold standard. The positivity rates in the Mp1p EIA, GM assay, and blood culture were 72%, 64.5%, and 81.7%, respectively, in the TSM group. The sensitivity, specificity, and positive and negative predictive values of the Mp1p EIA were 72.0% (67/93), 96.8% (184/190), 91.8% (67/73), and 87.6% (184/210), respectively. The Mp1p EIA showed a substantial agreement with the gold standard (kappa: 0.729) and superiority to the GM assay (kappa: 0.603); it also showed a superior diagnostic accuracy in the patients with CD4+ counts of < 50 cells/µL compared to those with CD4+ counts ranged from 50–100 cells/µL. The Mp1p EIA has the advantage of assisting in the early diagnosis of talaromycosis in patients with AIDS, especially those with low CD4+ counts.Supplementary InformationThe online version contains supplementary material available at 10.1007/s11046-022-00618-9.
Highlights
Talaromycosis is an invasive fungal disease caused by Talaromyces marneffei (T. marneffei), which is common in immunocompromised individuals, especially in patients with acquired immunodeficiency syndrome (AIDS)
In the non-Talaromyces marneffei (TSM) group, 6 patients had positive results on the Mp1p assay, none of whom were diagnosed with a fungal infection (Table S4)
We found that Mp1p antigen detection possesses a superior advantage in assisting in talaromycosis diagnosis in patients with AIDS within 3 days of admission, especially those with low CD4? counts (\ 50 cells/lL)
Summary
Talaromycosis is an invasive fungal disease caused by Talaromyces marneffei (T. marneffei), which is common in immunocompromised individuals, especially in patients with acquired immunodeficiency syndrome (AIDS). Count is a risk factor for talaromycosis, especially if the CD4? It is mainly prevalent in Southern China and Southeast countries, including Thailand, Vietnam, India, and Malaysia [3–7]. In Southern China, the prevalence of talaromycosis in hospitalized patients with AIDS has increased by 65% within 5 years [8]. Talaromycosis is a life-threatening disease with a high mortality rate of up to 50.6% without timely antifungal treatment [6, 9, 10]. Delayed diagnosis of talaromycosis is an important reason for its high mortality rate [10, 11]. For every day of delay in the diagnosis of talaromycosis, the risk of death increases by 2% [11].
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have